PE20090679A1 - Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 - Google Patents

Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3

Info

Publication number
PE20090679A1
PE20090679A1 PE2008001588A PE2008001588A PE20090679A1 PE 20090679 A1 PE20090679 A1 PE 20090679A1 PE 2008001588 A PE2008001588 A PE 2008001588A PE 2008001588 A PE2008001588 A PE 2008001588A PE 20090679 A1 PE20090679 A1 PE 20090679A1
Authority
PE
Peru
Prior art keywords
alkyl
antagonists
cycloalkyl
histamine
azacyclilisoquinolinone
Prior art date
Application number
PE2008001588A
Other languages
English (en)
Inventor
Dahui Zhou
Jonathan Laird Gross
Albert Jean Robichaud
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20090679A1 publication Critical patent/PE20090679A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE X ES (CR3R4)p, CO, O; R3 Y R4 SON CADA UNO H, HALOGENO, CICLOALQUILO, ALQUILO SUSTITUIDO O NO; R1 ES ALQUILO, CICLOALQUILO SUSTITUIDO O NO; R2 ES NR5R6, ALQUILO, CICLOALQUILO, ARILO, ENTRE OTROS; R5 Y R6 SON CADA UNO H, ALQUILO, ALQUENILO, ALCOXI, ENTRE OTROS; m Y p SON DE 0 -2; n ES DE 0-3. SON COMPUESTOS PREFERIDOS: 4-{[2-(1-CICLOBUTILPIPERIDIN-4-IL)-1-OXO-1,2,3,4-TETRAHIDROISOQUINOLIN-6-IL]OXI}BENZOICO; 4-{[2-(1-CICLOBUTILPIPERIDIN-4-IL)-1-OXO-1,2,3,4-TETRAHIDROISOQUINOLIN-6-IL]OXI}BENZOATO DE METILO; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE HISTAMINA 3 UTILES EN EL TRATAMIENTO DE ALZHEIMER, PARKINSON, HUNTINGTON, ESQUIZOFRENIA, ENTRE OTROS
PE2008001588A 2007-09-12 2008-09-11 Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 PE20090679A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99355407P 2007-09-12 2007-09-12

Publications (1)

Publication Number Publication Date
PE20090679A1 true PE20090679A1 (es) 2009-05-28

Family

ID=40261508

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001588A PE20090679A1 (es) 2007-09-12 2008-09-11 Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3

Country Status (23)

Country Link
US (1) US20090069370A1 (es)
EP (1) EP2200998A1 (es)
JP (1) JP2010539178A (es)
KR (1) KR20100054852A (es)
CN (1) CN101842366A (es)
AP (1) AP2010005199A0 (es)
AU (1) AU2008298983A1 (es)
BR (1) BRPI0816806A2 (es)
CA (1) CA2699383A1 (es)
CL (1) CL2008002708A1 (es)
CO (1) CO6300951A2 (es)
CR (1) CR11309A (es)
DO (1) DOP2010000078A (es)
EA (1) EA201000319A1 (es)
EC (1) ECSP10010032A (es)
MA (1) MA31700B1 (es)
MX (1) MX2010002899A (es)
NI (1) NI201000035A (es)
PA (1) PA8795601A1 (es)
PE (1) PE20090679A1 (es)
TN (1) TN2010000107A1 (es)
TW (1) TW200918062A (es)
WO (1) WO2009036117A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
JP2011213700A (ja) * 2010-04-02 2011-10-27 Nishizaki Soyaku Kenkyusho:Kk 認知症改善用組成物
WO2011143162A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
EP2569304A1 (en) 2010-05-11 2013-03-20 Sanofi Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
AR081498A1 (es) * 2010-05-11 2012-09-19 Sanofi Aventis Derivados de n-alquil -y n-acil-tetrahidroisoquinolina sustituidos, preparacion y su uso terapeutico de los mismos
AR083718A1 (es) 2010-05-11 2013-03-20 Sanofi Aventis Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas
WO2011143155A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
TW201206910A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
EP2535062A1 (en) 2011-06-13 2012-12-19 Dentsply IH AB Collagen coated article
US9295531B2 (en) 2011-06-13 2016-03-29 Dentsply International Inc. Collagen coated article
CA2850700C (en) * 2011-11-30 2019-11-12 F. Hoffmann-La Roche Ag New bicyclic dihydroisoquinoline-1-one derivatives
JO3442B1 (ar) * 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
AR098215A1 (es) 2013-10-29 2016-05-18 Takeda Pharmaceuticals Co Compuesto heterocíclico
CN112209876B (zh) * 2020-10-15 2022-08-26 华侨大学 一种3-三氟甲基异喹啉酮衍生物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
SE7907121L (sv) * 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
AU4319797A (en) * 1996-09-25 1998-04-17 Yamanouchi Pharmaceutical Co., Ltd. 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline derivatives or medicinal compositions thereof
DE69819539T2 (de) * 1997-05-01 2004-09-30 Eli Lilly And Co., Indianapolis Antithrombotische mittel
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
MXPA06013042A (es) * 2004-05-14 2007-02-12 Millennium Pharm Inc Compuestos y m??todos para inhibir la progresion mit??tica.
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
SE0401970D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
MX2007008843A (es) * 2005-01-21 2007-08-22 Schering Corp Derivados de imidazol y bencimidazol utiles como antagonistas de histamina h3.
US20070032475A1 (en) * 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
US8143284B2 (en) * 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
US7799806B2 (en) * 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators

Also Published As

Publication number Publication date
CA2699383A1 (en) 2009-03-19
EP2200998A1 (en) 2010-06-30
PA8795601A1 (es) 2009-05-15
WO2009036117A1 (en) 2009-03-19
AP2010005199A0 (en) 2010-04-30
CL2008002708A1 (es) 2008-10-10
JP2010539178A (ja) 2010-12-16
AU2008298983A1 (en) 2009-03-19
CN101842366A (zh) 2010-09-22
EA201000319A1 (ru) 2010-10-29
KR20100054852A (ko) 2010-05-25
ECSP10010032A (es) 2010-08-31
MX2010002899A (es) 2010-04-09
CO6300951A2 (es) 2011-07-21
BRPI0816806A2 (pt) 2015-03-10
TW200918062A (en) 2009-05-01
CR11309A (es) 2010-04-07
DOP2010000078A (es) 2010-04-15
US20090069370A1 (en) 2009-03-12
MA31700B1 (fr) 2010-09-01
TN2010000107A1 (fr) 2011-09-26
NI201000035A (es) 2010-07-15

Similar Documents

Publication Publication Date Title
PE20090679A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
AR055563A1 (es) Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20141120A1 (es) Compuestos heterociclicos
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20081530A1 (es) Nuevos compuestos 617
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20051142A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion para los mismos
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20091008A1 (es) Derivados heterociclicos como moduladores de fosfoinositida 3-cinasa
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales

Legal Events

Date Code Title Description
FX Voluntary withdrawal